Ten patients had ductal carcinoma in situ, and 93 patients had invasive breast carcinoma: 49 patients had the luminal A subtype; 11, luminal B1 (non-HER2 positive) subtype; 16, luminal B2 (HER2 positive) subtype; 9, HER-2-positive subtype; and 18, triple-negative subtype (Table 1). This evidence concerns the gene ERBB2 and invasive breast carcinoma.